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I. Introduction 
The field of medicinal chemistry requires efficient, novel drug development processes to 
sustain and advance the landscape of current pharmaceutical agents. To this end, fragment-based 
drug discovery (FBDD) is a methodology that aims to provide a balanced approach to the hit 
detection and lead optimization stage in the identification of small molecule agents (fragments). 
These small, low-molecular weight (mw<300 amu) molecules are employed in various 
biochemical assays to identify leads against a biological target. One challenge in FBDD is the 
synthesis of novel fragments containing heterocycles with a selective synthetic handle, a functional 
group designed to allow further modification. Heterocyclic fragments that allow for 
straightforward synthesis and modification are underrepresented in fragment libraries and offer the 
intriguing opportunity for rapid diversification into a fragment library from single, heterocyclic 
parent fragment. The imidazole is a heterocycle that presents a unique synthetic challenge for 
organic chemists, as current imidazole syntheses do not allow for regioselective synthesis of a 
1,2,4-substitued imidazole. The research herein describes the approaches taken towards the 
challenge of synthesizing the 1,2,4-substituted imidazole parent fragment containing a hydrophilic 
moiety, synthetic handle, and phenyl ring derivative.  
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II. Literature Review 
The History of Medicinal Chemistry 
Medicinal chemistry is the field of chemistry associated with designing, synthesizing, and 
implementing pharmaceutical agents, or bioactive molecules. Medicinal chemistry is an 
interdisciplinary science, drawing from organic chemistry, biochemistry, and molecular biology. 
Throughout the history of medicinal chemistry, independent advances in each of its constituent 
fields has prompted an advancement in the field of medicinal chemistry as a whole.1 
The synthesis and optimization of bioactive molecules first began with the isolation and 
purification of natural products. These naturally formed molecules displayed characteristics that, 
over the course of millions of years of evolution, were precisely fine-tuned to function within their 
respective biochemical pathways. For instance, Taxol (Figure 1a) is a natural anti-cancer agent 
first isolated from the bark of the Yew tree Taxis brevifolia in 1962. Taxol stabilizes the 
microtubules of cells during mitosis, in turn preventing the cell from proceeding to anaphase.2 This 
can result in a return to the cellular G0 phase, or even the initiation of apoptosis, thus making Taxol 
an attractive anti-cancer agent.3 Unfortunately, isolation of pure Taxol bark for the 
chemotherapeutic treatment of a single patient requires large amounts of tree bark from the T. 
Brevifolia tree. The National Cancer Institute (NCI) calculated that to treat all patients with ovarian 
cancer, 240 lbs. of Taxol 
would be required, meaning 
stripping (and thereby killing) 
a staggering 360,000 Yew 
trees.4 Thus, by the early 
1990s, over thirty research 
Figure 1: (A) Molecular structure of Taxol. (B) Molecular structure
of 10-deactylbaccatin III, or 10-DAB, a synthetic precursor to
Taxol.
A B
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groups were independently attempting a total synthesis of Taxol. The first total synthesis was 
successfully completed in 1994 by Nicolaou et al. and consisted of a complex convergent pathway 
with forty steps and an overall yield of 0.03%.5 While an important step for the commercial use of 
Taxol, researchers then aimed to optimize the synthetic pathway. A semisynthetic route was 
developed by Holton et al. that started from the precursor 10-deacetylbaccatin III, or 10-DAB 
(Figure 1b), which was isolated from the needles of the Taxus baccata English Yew Tree.6 The 
needles, a renewable source of 10-DAB, allowed researchers to optimize the total synthetic 
pathway to a commercially viable semisynthetic pathway. Taxol is thus an archetypal example of 
medicinal chemistry, including the process of isolating, characterizing, and attempting to develop 
total synthetic pathways towards natural products. It also represents the challenge of medicinal 
chemistry: to not only develop drugs, but to develop commercially viable, industrial-scale 
synthetic routes towards those drugs. 
This traditional drug discovery paradigm has changed over the past several decades. Due 
to the advent of new spectroscopic and analytical techniques, particularly in the fields of organic 
chemistry, biochemistry, and structural/computational biology, medicinal chemistry has 
progressed from a field limited by the discovery of natural products to a field concerned with 
designing novel synthetic molecules. In particular, the development of nuclear magnetic resonance 
(NMR) spectroscopy, mass spectrometry (MS), and high-performance liquid chromatography 
(HPLC) all played crucial roles in the advancement of organic chemistry and thus medicinal 
chemistry.7 
Additionally, advancements in the computational power available to researchers 
contributed to the development of digitally rendered biological targets.  Now, computer 
simulations of drug-biomolecule interactions allow medicinal chemists to develop and test novel 
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drug molecules without wasting physical resources, such as time and money, allowing for more 
intelligently designed experimentation and more efficient exploration of pharmacophores, or 
common functional groups possessing beneficial physiochemical properties. 
High-Throughput Screening 
Along with these advancements in organic chemistry and structural biology, medicinal 
chemists and biochemists began to develop methodologies to take advantage of this emergent 
technology and increase the rate of compound or hit identification. High-Throughput Screening 
(HTS) is a methodology of drug discovery that employs robotics, data processing software, and 
liquid-handling devices to screen multiple compounds (in the range of thousands to millions) 
against biological targets. HTS combines several attractive features, including efficiency, with 
some HTS systems being capable of screening upwards of 10,000 compounds in one day. 
Additionally, HTS possesses an advantage in resource management: robotic liquid handling 
devices are capable of dealing with much smaller quantities than human researchers. HTS 
molecule libraries often number into the millions, and often include molecules synthesized for 
another purpose (i.e. a drug previously synthesized for a specific protein interaction). HTS 
employs molecules with molecular weights between 400 and 600 Da, which are inherently 
complex.8 HTS does have its drawbacks, however, including the cost of the robotic operating 
system, as well as the complexity of the compounds screened as potential drug molecules.  
Complexity Theory 
HTS has led to the discovery, optimizations, and implementation of successful drugs across 
different disease states. Despite the success of these drugs, some medicinal chemists began to 
question the practicality of screening such large molecules and re-optimizing fully formed hit 
molecules.9 This idea led to the development of complexity theory. Complexity theory is a theory 
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in drug discovery that was developed by Leach and Hann, computational chemists who sought to 
address the problem of covering chemical space. Their paper, initially written in 2001, attempted 
to reconcile the seemingly impossible vastness of chemical space, which was estimated in the late 
1990s to be as high as 1050 possibly relevant chemical structures, with the rapidly expanding HTS 
methodology. Leach and Hann essentially urged medicinal chemists to cease screening millions 
of complex molecules against various biological targets, as the likelihood of obtaining a hit from 
these complex molecules was infinitesimal. Further, even if an attractive drug molecule was to be 
obtained, its inherent complexity reduced its synthetic tractability and thus a lead optimization 
stage was even more unlikely.10  
As seen in Figure 2a, the complexity theory developed by these authors modeled both 
potential biological targets, such as enzymes or other proteins, and potential drug molecules 
(ligands) as linear chains of + and – signs. Favorable biochemical interactions (a broad term 
encompassing H-bonds, Van der Waals interactions, salt bridges, etc.)  occurred between + and – 
signs or vice versa. It was found that the probability for favorable interactions (blue line) decreased 
rapidly with an increase in the length of the ligand, which is representative of the size of the 
+
+
+
−
−
−
−
−
−
+
−
+
+
+
Figure 2: (A) The basis of the modeling system of complexity theory in drug discovery, which
models both biological targets and potential drug molecules (ligands) as an arbitrary series of + and
− signs, with favorable interactions (H-bonds, salt bridges, etc.) occurring between + and − signs.10
(B) The results of the simulation, which suggest that smaller molecules represent better starting
points for the drug discovery process.11
B A 
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potential drug molecule. The increase in ligand size thereby increased the number of interactions 
required for a useful binding event and lowered the probability of the occurrence of such a binding 
event. Conversely, the probability of measuring the binding event (green line) increased with 
ligand size, meaning that a binding event with more interactions is potentially easier to observe. 
While the obvious solution was to therefore produce very small molecules with favorable 
characteristics, the probability of detecting a binding event between an extremely small ligand and 
a target biomolecule decreased as the ligands approached a certain size. Thus, an optimal range 
exists between molecule size and the number of binding interactions (purple line) that balances the 
maximum probability for a favorable interaction and the probability of binding event detection 
(Figure 2b).10  
Complexity theory, which essentially states that relatively small potential drug molecules 
form a greater number of quality, favorable interactions at the expense of being harder to detect, 
formed the basis of Fragment-Based Drug Discovery (FBDD).11 FBDD is a methodology of 
medicinal chemistry that was developed to answer the question posed by complexity theory, 
attempting to strike a balance between ligand size and the probability for favorable interactions. 
Thus, the potential drug molecules being screened are decidedly smaller than those screened in 
HTS. Their size, though, is their most attractive feature; in addition to resolving the question posed 
by Complexity Theory, these fragments allow for a more efficient exploration of chemical space 
via their capability for being optimized into a variety of larger molecules.12 
Fragment-Based Drug Discovery 
FBDD encourages the design and synthesis of novel fragment molecules that will explore 
chemical space efficiently. The design of these fragments is limited by several core tenants. The 
first of these tenants is an adherence to the Rule of Three.13 The Rule of Three, which was formed 
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by Congreve et. al in a review of existing fragment libraries, posits that the ideal fragment molecule 
includes a molecular weight < 300 Da, a number of hydrogen bond donors and acceptors (each < 
3), a predicted clogP (a partition coefficient that measures a compounds preference for a polar 
aqueous medium vs. nonpolar octanol) < 3, a number of rotatable bonds < 3, and a polar surface 
area < 60 Å2.13 Thus, fragment molecules are small, abiding by a variety of parameters to increase 
the probability of a binding event to a target biomolecule and allowing for further optimization 
into a larger molecule while maintaining favorable physiochemical properties. Beyond the simple 
parameters outlined in the Rule of Three, many other metrics exist to describe the potency of these 
drug molecules in a manner that allows for comparison across vastly different pharmacophores, 
ranging from simple heterocycles to larger compounds possessing a variety of functional groups. 
These metrics for analysis, which are gathered from a 2013 review describing the various metrics 
and their respective benefits, are designed to work in conjunction with one another and to describe 
the potency and binding affinity of a molecule in a manner that also accounts for the differences 
in solubility, lipophilicity, and size of the fragment molecules.14  
Molecular Optimization via Composite Parameters 
The most popular parameters, such as ligand efficiency, binding efficiency, and lipophilic 
efficiency normalize the efficacy of the fragments based on size and hydrophobicity of the 
fragments. Together, these metrics provide a quantitative measurement of the characteristics of the 
molecule, instead of simply measuring potency. Ligand efficiency (LE) is perhaps the most 
fundamental descriptor for a fragment, describing the ratio of the Gibbs free energy of binding to 
the number of non-hydrogen atoms within the fragment.15 LE describes the binding affinity of a 
ligand to a target biomolecule corrected for its size in number of atoms, and is an important metric 
to FBDD. Reynolds et al. examined the ligand efficiency metric in the context of several thousand 
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drug molecules and found results similar to those posed by the complexity theory: maximal ligand 
efficiency occurred in fragment molecules (< 20 non-hydrogen atoms) and decreased sharply as 
the molecules grew larger.16 Thus, while ligand efficiency is an attractive choice for early in the 
lead development stage, as the fragments are later merged, linked, or grown, other metrics become 
more applicable.16 The binding efficiency index (BEI), attempts to correct LE for its treatment of 
all non-hydrogen atoms as equivalent atoms.15 For example, the molecule toluene (Figure 3) 
would be considered equivalent to the molecule bromobenzene in terms of ligand efficiency, as 
both have 7 non-hydrogen atoms. This treatment by LE, however, fails to consider the vast 
difference in molecular weight between toluene (92 g/mol) and bromobenzene (157 g/mol). This 
weight consideration, which has serious pharmacological implications, receives proper treatment 
from the BEI metric, which accounts for the potency of the drug molecule and the molecular 
weight.17 Lipophilic efficiency (LipE) accounts for a given drug molecules’ potency in the context 
of its lipophilicity.14 The preference of a compound for aqueous or non-aqueous media is an 
extremely important factor in drug development. The structures of target biomolecules are dictated 
by the same non-covalent interactions that govern a compounds 
ability to selectively and efficiently bind, among those being the 
hydrophobic effect. This phenomenon allows for medicinal 
chemists to design compounds that take advantage of a 
compounds preference for hydrophilic or hydrophobic active 
sites.18 
 
 
 
MW = 92 g/mol
HAC = 7
MW = 157 g/mol
HAC = 7
Figure 3: Comparison of the structure
of toluene to bromobenzene and the
respective molecular weights and
heavy atom count of each molecule,
which receive the same treatment
from the LE parameter but vary in
their BEI.
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Heterocycles in Drug Discovery 
An important motif in drug design are heterocycles—cyclic arrangements of atoms 
containing elements other than just carbon and hydrogen, such as oxygen, nitrogen, and sulfur.19 
Heterocyclic rings are present in many synthesized and marketed drug molecules today, including 
Aripiprazole, Lovastatin, and Duloxetine, which were listed as the 6th, 10th, and 11th most popular 
drugs of 2013 from worldwide sales (Figure 4).20  Heterocycles have unique properties, including 
higher levels of electronegativity spread across a conjugated system compared to aromatic rings 
composed of solely carbon and hydrogen atoms. This general area of electron density makes them 
favorable moieties for interacting with positive pockets in biomolecules, as well as possibly 
assisting in chelating cofactors by donating or accepting electrons to the d-orbitals of transition 
metals.19 Additionally, the planarity of heterocycles allows them to access pockets in biomolecules 
that bulky, branched moieties cannot. Heterocycles are a form of bioisosteres—compounds with 
chemical structures similar to those found in biological systems that produce similar biochemical 
effects. As oxygen, sulfur, and nitrogen are common elements found in biomolecules, medicinal 
chemists attempt to simulate these structural motifs with heterocycles.19 The diversity and 
complexity of heterocycles has attracted attention in recent years, with Pitt et al. publishing a large 
Piperazine
Piperidine
Pyrimidine
Thiophene
A CB
Figure 4: The 6th, 10th, and 11th top-selling drugs in 2013, each of which contain heterocyclic moieties.
(A) Aripiprazole (trade name Abilify®), which contains piperazine and piperidine rings; (B) Rosuvastatin
(trade name Crestor®), which contains a pyrimidine ring; (C) Doloxetine (trade name Cymbalta®), which
contains a thiophene ring. These drugs represent the possible variety and complexity afforded by
heterocycles.
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list of envisioned heterocycles of the future in the Journal of Medicinal Chemsitry.21,22 These 
heterocycles represent a small facet of the vast chemical space that has yet to be explored and 
synthesized. While seemingly simple, these ring systems present interesting and unique synthetic 
challenges.  
Imidazoles in Drug Design 
 One heterocycle of particular interest to medicinal chemists is the imidazole, planar five-
membered ring containing two nitrogen atoms at positions 1 and 3 (Figure 5). The imidazole is 
unique in its planarity and the electronic environment created by the placement of its nitrogen 
atoms, as well as its classification as a bioisostere. Additionally, imidazoles are amphoteric, and 
are thus capable of acting as both an acid and a base. The arrangement of the nitrogen atoms at 
positions 1 and 3 allows for resonance and movement of the positive and negative charges across 
the ring, further increasing its versatility. Imidazole rings are prevalent in nature, being the main 
component of the amino acid histidine, the related hormone histamine, and upon binding to a 
pyrimidine ring, are able to form purines (the most common nitrogen-containing heterocycle in 
nature) (Figure 5).  As such, they present a valuable synthetic target for medicinal chemists 
attempting to mimic biological structures to achieve a physiochemical effect.  
 For example, azoles (a family 
of nitrogen-containing heterocycles 
that includes the imidazole) are 
integral components of antifungal 
drugs.23 The enzyme lanosterol-14α-
demethylase is a hemoprotein that 
catalyzes the removal of a methyl 
A B
Figure 5: (A): Numbering system for the imidazole ring. (B): Several of
the possible resonance structures attainable by movement of the
electrons across the conjugated surface of the imidazole. (C) The
biosynthetic pathway from the amino acid histidine (left) to the hormone
histamine (right).
C
 
Lafferty 14 
group from the fungal steroid precursor lanosterol. The 
de-methylated lanosterol is subsequently converted to 
ergosterol, an important component to fungal 
membranes.24 Thus, antifungal drugs target lanosterol-
14α-demethylase to inhibit lanosterol conversion and 
thereby reduce fungal membrane stability. Azole-
containing drug molecules inhibit lanosterol-14α-
demethylase by mimicking histidine residues and binding 
selectively to the heme group of the active site, thereby 
functioning as a noncompetitive inhibitor. (Figure 6).24 
Azole-containing antifungal drugs are only one example of the advantages offered by the 
bioisosteric molecules. Imidazoles are prevalent in other pharmaceutical contexts, including 
antibiotics (nitroimidazoles), central nervous system stimulants (theophyllines), and anticancer 
medication (mercaptopurines).25 
Fragment Library Design 
 Beyond the attractive features of the imidazole ring itself, the synthesis of imidazoles 
presents an opportunity to selectively modify the substituents of the ring at various positions. The 
incorporation of a variety of moieties onto the imidazole ring allows medicinal chemists to design 
potential drug molecules that contain both imidazole and its advantageous bioisosteric properties 
along with substituents that can increase certain physiochemical properties, such as lipophilicity 
or potency. Imidazole-based drug molecules with selective substituents also present an attractive 
avenue for drug design when considering Complexity Theory; the small size of the imidazole and 
its selectively modifiable nature are favorable qualities for a fragment entering drug development.  
Figure 6: Modeled interaction between
imidazole-containing drug and the
heme group of CYP51, a lanosterol-
14α-demethylation protein (isolated
from wheat pathogen Mycosphaerella
graminicola).
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Fragment libraries are defined by the size of their constituent potential drug molecules, and 
thus the imidazole can be considered a suitable basis for a fragment library. Fragment libraries, as 
they are known, are commercially available to medicinal chemists looking to explore certain 
biomolecules. Fragment libraries, which are typically in the range of 500 to 10,000 fragments, 
contain a wide variety of molecules, in an attempt to cover the maximum amount of chemical 
space. While fragment libraries do present a solution to the problem posed by the complexity 
theory, providing researchers with a balanced mix between hit detection and probable interaction, 
there are limitations to this approach.26 The market for fragment libraries is saturated with libraries 
containing redundant molecules that are limited in their ability to interact with a wide variety of 
targets. Many libraries contain fragments with nearly identical pharmacophores, functional groups, 
and overall structures. Additionally, certain heterocycles like the imidazole are underrepresented 
in current fragment libraries, especially those with modifiable, asymmetrical substituents. To 
address these issues, one can envision designing and synthesizing a library of multi-variant 
fragments that possess the previously underrepresented imidazole core and selectively placed 
substituents. 
Traditional Imidazole Syntheses 
Thus, a synthesis must be developed that allows for the synthesis of imidazole-containing 
fragments with selective substituents at certain positions on the imidazole ring. Synthesis of the 
imidazole is commonly associated with the Debus-Radziszewiski method (Figure 7a), which was 
developed in 1882 and affords an imidazole with selective substituents at positions 2, 4, and 5.27 
Attempts to access the various positions of the imidazole, including the 1 and 4 positions, have 
been made as early as 1994 by Sorrell et al., who achieved selectively modified 1,4 imidazoles in 
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yields averaging 36% 
(Figure 7b).28 Pooi et 
al. produced similar 1,4 
imidazoles in 2014 
with much higher 
yields by employing 
isocyanate derivatives, 
but still lacked the 
selectivity of 
substituting the 2 
position (Figure 7c).29 
To date,  selective and 
controlled access to the 
1, 2, and 4 positions of 
the imidazole core has 
not been achieved in literature. The most similar molecule to the 1,2,4-imidazole was synthesized 
by Eidam et al. as an intermediate (imidazole 6), but was not properly isolated in pure yield (Figure 
7d).30 A valuable and novel synthetic target, then, is an imidazole-containing fragment molecule 
with selectively accessible 1, 2, and 4 positions, containing moieties allowing for subsequent 
modification and thus diversification into a wide variety of potential drug molecules. The rewards 
for accomplishing this goal are twofold: accessing the 2 position, in addition to the 1 and 4 
positions, provides an unprecedented level of substituent control on the imidazole, and this control 
provides further possibilities for covering chemical space.  
Figure 7: Comparison of previous attempts to synthesize substituted imidazole
with selective control over various positions, including (A) the Debus-
Radziszewski method (1882) with 2,4,5 selectivity, (B) Soller et al. (1994) with
1,4 selectivity, harsh reaction conditions, and low yield (C) Pooi et al. (2014)
with 1,4 selectivity, milder reaction conditions, and higher yield, and (D) Eidam
et al. (2011) which confers the desired 1,2,4 selectivity but was not properly
isolated in pure yield.
A
B
C
D
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Figure 8 shows the structure of the 1,2,4-imidazole, the archetypal 
target molecule of this research. The archetypal 1,2,4-imidazole has 
several interesting features, including the heterocyclic imidazole, a 
hydrophobic phenyl core, a synthetic handle providing synthetic 
tractability, and a hydrophilic carboxylic acid moiety.  
Synthetic Tractability via the Alkyne Handle 
The synthetic handle, or alkyne, is particularly interesting 
for its ability to facilitate a variety of future synthetic steps. As seen in Figure 9, various synthetic 
pathways are possible, including basic synthetic steps such as nucleophilic attacks or reduction, to 
more advanced techniques 
such as Sonogashira coupling 
or Click chemistry. The 
Sonogashira coupling is a 
palladium-catalyzed cross-
coupling reaction between a 
terminal alkyne and an aryl or 
vinyl halide.31 Interestingly, 
while the aryl group is 
traditionally an aromatic 
hydrocarbon, successful 
Sonogashira coupling has been 
achieved with heteroarene 
systems by employing a hybrid gold-palladium catalyst.32 Sonogashira coupling is an example of 
Figure 8: The structure of the target
molecule, 1, and the numbering system
of the imidazole core, resulting in its
description as a selectively modified
1,2,4-imidazole. Highlighted are the
carboxylic acid moiety (blue), the
alkyne synthetic handle (red), and the
hydrophobic phenyl ring (green).
1
Sonogashira
Cross-Coupling
Acetylide 
Nucleophile 
Addition
Catalytic 
Hydrogenation 
(cis/trans)
Huisgen
Cycloaddition 
(Click)
Figure 9: Schematic displaying the synthetic tractability of the terminal alkyne 
moiety, including modification to a triazole (2), coupling to an aryl moiety (3), 
alkylation via nucleophilic attack (4), and hydrogenation (5). 
3
4
5
2
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one of the three methodologies by which fragments are expanded upon: merging, linking, or 
growing. Sonogashira coupling allows for fragment growing and the addition of possibly favorable 
moieties, including those that increase thermodynamic stability or binding interactions.33 Click 
chemistry refers to reactions that are easy to perform, produce benign or easily-removed side 
products, are stereospecific, and are wide in scope.34 Click chemistry was developed in response 
to a need in medicinal chemistry for widely applicable reactions that optimize diversity and the 
coverage of chemical space while balancing reagent economy. Click chemistry allows for the 
rapid, efficient development of a wide variety of fragments from an initial archetype, such as the 
1,2,4-imidazole. The alkyne substituent of the 1,2,4-imidazole can participate in reactions 
classified as Click reactions, such as a Copper(I)-Catalyzed Huisgen Cycloaddition, resulting in a 
1,2,3-triazole (Figure 9).35 The formation of the 1,2,3-triazole in conjunction with an imidazole 
continues the motif of heterocycle exploration. Further, if the azide reagent could be prepared on 
the phenyl ring of the 1,2,4-imidazole, the possibility exists for an intramolecular ring closure, 
resulting in an imidazole-triazole-phenyl tricycle. Such diversity, within the scope of a single Click 
reaction, exemplifies the synthetic tractability of the alkyne moiety. Alkynes are also an attractive 
choice for nucleophilic attack due to their weak acid nature, and conversely the nucleophilicity of 
their conjugate base, the acetylide ion. Substituted acetylides are powerful nucleophiles that can 
effectively attack acids with a pKa lower than 25. Additionally, alkynes present an opportunity for 
reduction reactions, particularly catalytic hydrogenation reactions. Based on the metal catalyst 
employed, different geometries of alkenes can be obtained (cis or trans), thereby increasing the 
alkyne’s ability as a synthetic handle with more opportunities for stereospecific addition 
reactions.36,37 
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Design Considerations at the 1- and 4-Positions 
Beyond the alkyne handle and the possible substituents associated with its synthetic 
tractability, the other moieties of the 1,2,4-imidazole possess equally important purposes. The 
carboxylic acid at position 4 is a hydrophilic moiety, and thus has implications for a potential 
fragment’s lipophilicity and binding capabilities in biochemical pockets. If a target biomolecule 
has a pocket with, for instance, residues capable of forming ionic salt bridges such as arginine or 
lysine, the carboxylic moiety will participate in these interactions.38 On the other hand, the moiety 
may achieve thermodynamic stability by interacting with water molecules outside the biomolecule, 
allowing the other portions of the 1,2,4-imidazole to contact specific inner residues. The 
hydrophobic core of the 1,2,4-imidazole, including the imidazole itself and the possible phenyl 
derivatives of position 1, participate in other interactions. Specifically, free rotation about the bond 
at position 1 allows for planar interactions in three dimensions. Heterocycles are important not 
only for their planarity, but the extended pi electron cloud that exits on its conjugated surface. 
Cations present in biochemical pockets, such as the positive residues lysine and arginine, can 
interact with this pi-cloud. Heterocycles present an attractive choice for bioisosteric replacement 
due to their ability to increase potency, lipophilicity, participate in noncovalent interactions, and 
polarity.39 These parameters can be quantified and optimized by employing the metrics outlined 
above, such as LE or LipE. As such, the hydrophobic core of the 1,2,4-imidazole has a variety of 
potential applications in fragment design.  
Specific Aims 
The primary goal of this thesis is the successful synthesis of the 1,2,4-imidazole in pure 
yield. For the reasons outlined above, the 1,2,4-imidazole is an attractive archetypal fragment that 
achieves a level of selectivity and synthetic tractability not yet produced in literature. Beyond this 
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archetypal fragment, modifications to the 1 and 2 positions have 
been attempted to demonstrate the possible complexity afforded 
by this molecule in simple synthetic steps (Figure 10). These 
include placement of both an alkyne synthetic handle and 
primary amine at position 2, as well as the incorporation of 
various phenyl derivatives (with moieties including electron 
donating, electron withdrawing, aliphatic, and heterocyclic 
groups) at position 1. Various heterocycles and phenyl 
derivatives have been successfully integrated into the 
intermediate molecule. These moieties will eventually constitute the basis of the substituted 1,2,4-
imidazole fragment library. 
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 7
8 9
Figure 10: The goals of this thesis include
the synthesis of the 1,2,4-imidazole and
subsequent derivatives with selectively
modifiable substituents at both positions 1
and 2.
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III.  Experimental Procedures 
 
General: Reagents used throughout the research were purchased from Sigma-Aldrich Chemicals, 
Oakwood Chemicals, and Combi-Blocks Chemicals and used without further purification. All 
NMR spectra were obtained with a JEOL 300 MHz NMR and recorded at room temperature. 1H 
chemical shifts are reported in δ values in ppm downfield with the deuterated solvent as the internal 
standard. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = 
triplet, q = quartet, br = broad, m = multiplet, coupling constant (Hz), and integration. Thin-layer 
chromatography was conducted on Silicycle 200 µm aluminum-backed plates (F-254 indicator). 
Flash column chromatography was conducted with Silicycle silica gel (40-63 µm, 55Å	 pore 
diameter). 
General Procedure for Enamine Intermediates 10a-10i 
To a stirred solution of acetic acid (1 mL) in ethanol (5 mL) was added appropriate aniline (7.5 
mmol, 1 equiv) and TOF (1.98 mL, 15 mmol, 2 equiv). The reaction mixture was heated to reflux 
at 90°C for 2 hours. The reaction mix was allowed to cool to room temperature and nitroacetic 
acid ethyl ester (1.21 mL, 7.5 mmol, 1 equiv) was added to the flask. The reaction mix was again 
heated to reflux at 90°C for 3.5 hours. The reaction flask was placed in a -20°C freezer overnight. 
The recrystallized product was filtered in vacuo and washed with ethyl ether (2 x 10 mL). Products 
Scheme 1: Synthesis of enamine intermediate 10 from appropriate aniline, ethyl nitroacetate 
ethyl ester, and triethyl orthoformate in the presence of acetic acid and ethanol. 
10 
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10a-7i were all produced via similar procedures, with differences noted in the appropriate 
experimental section.  
 
 
 
 
 
Ethyl (Z)-3-anilino-2-nitroacrylate (10a): Procedure was followed as outlined to produce yellow 
powdery solid; 1.404 g, 79% yield; 1H NMR (300 MHz, CDCl3) 𝛿 10.93 (d, 1H), 9.05 (s, 1H), 
8.50 (s, 1H), 7.46-7.28 (m, 5H), 4.35 (q, 2H), 1.33 (t, 3H); 13C NMR (300 MHz, CDCl3) 𝛿 149.5, 
145.5, 138.0, 130.3, 126.7, 118.3, 61.7, 14.4.  
 
 
 
 
 
 
Ethyl (Z)-3-(m-anisidino)-2-nitroacrylate (10b): Procedure was followed as outlined to produce 
light yellow powdery solid; 1.68 g, 84% yield; 1H NMR (300 MHz, CDCl3) 𝛿 11.07 (d, 1H), 9.03 
(s, 1H), 8.51 (s, 1H), 7.36 (t, 1H), 6.81-6.75 (m, 3H), 4.34 (q, 2H), 3.84 (s, 3H), 1.35 (t, 3H). 
 
 
 
 
 
 
Ethyl (Z)-2-nitro-3-(3-pyridylamino)acrylate (10c): Procedure was followed as outlined to 
produce black, oily solid; 1.15 g, 93% yield; 1H NMR (300 MHz, CDCl3) 𝛿 11.00-10.86 (m, 1H), 
9.02 (d, 1H), 8.54 (m, 3H), 7.50 (d, 1H), 4.40 (q, 2H), 1.37 (t, 3H). 
 
 
 
 
 
 
Ethyl (Z)-3-(p-anisidino)-2-nitroacrylate (10d): Procedure was followed as outlined to produce 
bright orange powdery solid; 1.51 g, 76% yield; 1H NMR (300 MHz, CDCl3) 𝛿 11.21 (s, 1H), 9.01 
(s, 1H), 8.47 (s, 1H), 7.31-6.98 (m, 4H), 4.39 (q, 2H), 3.84 (s, 3H), 1.38 (t, 3H). 
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Ethyl (Z)-2-nitro-3-(p-nitrophenylamino)acrylate (10e): Procedure was followed as outlined to 
produce tan, slightly yellow powdery solid; 1.784 g, 85% yield; 1H NMR (300 MHz, CDCl3) 𝛿 
11.00 (s, 1H), 9.03 (s, 1H), 8.54 (s, 1H), 8.33 (s, 1H), 7.35-7.32 (m, 2H), 4.43 (q, 2H), 1.43 (t, 3H). 
 
 
 
 
 
 
Ethyl (Z)-3-(cyclohexylamino)-2-nitroacrylate (10f): Procedure was followed as outlined, and 
after unsuccessful recrystallization, compound 10f was purified through column chromatography 
(0-100% EtAc:Hex, collected 85-100% EtAc:Hex) after unsuccessful recrystallization and was 
dried in vacuo overnight, yielding a yellow, oily solid; 1.16 g, 64% yield; 1H NMR (300 MHz, 
CDCl3) 𝛿 9.46 (s, 1H), 8.67 (s, 1H), 8.12 (s, 1H), 7.55 (s, 1H), 5.15 (s, 1H), 4.34 (q, 2H), 2.02-
1.68 (m, 6H) 1.34 (t, 3H). 
 
 
 
 
 
 
Ethyl (Z)-2-nitro-3-(o-nitrophenylamino)acrylate (10g): Procedure was followed as outlined to 
produce yellow, powdery solid; 0.254 g, 18% yield; 1H NMR (300 MHz, CDCl3) 𝛿 9.06 (s, 1H), 
8.31 (s, 1H), 7.78 (t, 1H), 7.57 (s, 1H), 7.36 (t, 2H), 4.51 (q, 2H), 1.44 (t, 3H). 
 
 
 
 
 
 
Ethyl (Z)-3-(p-anilinophenylamino)-2-nitroacrylate (10h): Procedure was followed as outlined 
to produce gold/brown fine powdery solid; 0.920 g, 56% yield; 1H NMR (300 MHz, CDCl3) 𝛿 
11.25 (s, 1H), 10.99 (s, 1H), 8.99 (s, 1H), 8.48 (s, 1H), 7.35-7.30 (m, 3H), 7.05-7.00 (m, 3H), 5.83 
(s, 2H), 4.38 (q, 2H), 1.40 (t, 3H).  
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Ethyl (Z)-3-(3-isoxazolylamino)-2-nitroacrylate (10i): Procedure was followed as outlined to 
produce light pink, fluffy solid; 0.4668 g, 43% yield; 1H NMR (300 MHz, CDCl3) 𝛿 10.63 (s, 1H), 
8.97 (d, 1H), 8.62 (d, 1H), 4.37 (q, 2H), 1.37 (t, 3H). 
 
 
 
 
 
 
 
 
General Procedure for Synthesis of Imidazole 11 
 
To a solution of AcOH (5 mL) and TOF (0.71 mL, 4.2 mmol, 5 equiv.) was added compound 10a 
(200.0 mg, 0.84 mmol, 1 equiv.) and granular Fe (237.0 mg, 4.2 mmol, 5 equiv.). The reaction mix 
was refluxed at 85°C and stirred magnetically under N2 for 5 hrs. Over 5 hrs, 6 total equiv Fe and 
6 total equiv TOF were added to the reaction mix as it continued to reflux. After 5 hrs, the reaction 
mix was dried in vacuo. Any remaining acetic acid was neutralized with NaOH, and the product 
was washed with NaOH and brine (3x each). The product was purified by column chromatography 
(0-100% EtAc:Hex, collected 35%-100% fraction) and dried in vacuo. 
 
 
 
 
 
 
 
 
N-phenyl-2H-5-ethyl ester imidazole (11): light yellow solid; 47.6 mg, 26% yield; 1H NMR (300 
MHz, CDCl3) 𝛿 7.96 (s, 1H), 7.86 (s, 1H), 7.55-7.40 (m, 5H), 4.41 (q, 2H), 1.41 (t, 3H); 13C NMR 
(300 MHz, CDCl3) 𝛿 175.5, 134.1, 133.3, 133.2, 132.7, 128.7, 122.6, 61.5, 16.8. 
Scheme 2: Synthesis of imidazole 11 from enamine intermediate 10a and TOF in the 
presence of Fe and AcOH. 
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IV. Results and Discussion 
Overview 
 The overall reaction 
towards 11 is shown in Scheme 3, 
with the enamine intermediate first 
being produced in the first 
reaction, and subsequently 
reduced and cyclized into the 
imidazole in the second reaction. 
Opportunities for accessing the 1 
and 2 positions of the 1,2,4-imidazole exist in the first and second reactions, respectively. The first 
reaction, the synthesis of the enamine, offered access to 1 position of the imidazole by employing 
various derivatives of aniline. Research into this reaction explored optimizing yield and 
synthesizing a variety of enamine intermediates with different aniline derivatives. 
Mechanism of Enamine Formation 
 The enamine intermediate became a crucial step towards synthesizing imidazole 6 due to 
the inherent opportunity for modifying the aniline reagent, and thus inserting a new moiety on the 
1-position. The suggested mechanism of this reaction (Figure 11) occurs via a series of 
nucleophilic attacks; as seen in the highlighted portion of Figure 11a, the acid-catalyzed 
nucleophilic attack of the protonated aniline (or appropriate aniline derivative) is crucial to the 
procession of the reaction. The first nucleophilic attack forms the imine 12. As seen in Figure 11b, 
the next nucleophilic attack of the resonance-stabilized enol form of the ethyl ester nitroacetic ester 
A
B
C
Scheme 3: Synthetic pathway towards 11, which occurs via (A) the
production of the enamine intermediate 10a and (C) reduction and
cyclization of the intermediate 10a, resulting in 11. The 1-position of
the 1,2,4-imidazole can be accessed by replacing the aniline
nucleophile with aniline derivatives (B).
10a
10
11
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(13) on the imine 12 is 
akin to an aldol 
condensation, but with 
an amine rather than a 
hydroxyl group being 
present at the β-carbon 
and elimination of an 
ethanol molecule 
rather than a water 
molecule from the α−β 
bond. The first step of 
the suggested 
mechanism can also be considered analogous to the first step of the Knoevenagel condensation, 
which employs a catalytic piperidine (analogous to the aniline) to perform a nucleophilic attack an 
electron-rich aldehyde/ketone (analogous to the TOF).40 
Characterization of Product 10a 
The 1H NMR of 
the formed 
product 10a is 
shown in Figure 
12. Of particular 
notice is the 
presence of 
12
12
10a
A B
Figure 11: The mechanism of the synthesis of the enamine intermediate 10a, beginning
with (A) the nucleophilic attack of the aniline on TOF, resulting in the formation of the
imine intermediate 12. This is followed by (B) the nucleophilic attack by the resonance-
stabilized enol 13 on the imine, and then elimination of the α-carbon-imine bond,
affording the enamine 10a.
13
Figure 12: 1H NMR of the enamine intermediate 10a.
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multiple peaks corresponding to only 1 proton; this is attributed to the presence of cis and trans 
isomers in the enamine intermediate. Since one isomer is not particularly necessary for future 
reduction and cyclization (although the cis isomer is preferred due to the spatial considerations of 
forming the imidazole ring between the nitrogen atoms), further purification of the enamine 
product was not necessary and thus not pursued. The 1H NMR therefore displays two peaks for 
each proton, as each is exposed to a different electronic environment due to free rotation about the 
pi-bond. The protons of the trans isomer of the enamine are pushed further downfield due to the 
electronegativity of the nitro and ester moieties. 
Optimization of Enamine Synthesis 
Before exploring the effect of substituting moieties on the aniline derivative, considerations 
were made for the optimization of the enamine synthesis, including the order of reagent addition 
and product retrieval via recrystallization. The protocol detailed in the patent by Eidam et. al called 
for the addition of TOF after 2 hours of allowing aniline, ethyl nitroacetate, acetic acid, and ethanol 
to react. This procedure formed the intermediates shown in Figure 13. Upon realizing that the 
combination of aniline and the ethyl nitroacetate produced only the protonated aniline 14 and the 
resonance-stabilized enol form of 
the ethyl nitroacetate 13, and the 
bond forming events of the reaction 
occurred only after the addition of 
TOF, the effect of reagent addition 
order was tested on the yield. The 
synthesis of 10a was compared 
using two reactions: one following 
Figure 13: Comparison of the effect of order of reagent addition on
enamine synthesis based on the intermediates formed. Comparison
occurred between (A) protocol outlined by Eidam et al., which
produced protonated aniline 13 and resonance-stabilized enol form of
nitroacetic acid ethyl ester 14 , and (B) newly-designed protocol which
produced mechanistically appreciable imine 12.
12
13 14
A
B
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the protocol written by Eidam et. al (Figure 13a), as well as another protocol, in which TOF was 
added and ethyl nitroacetate was withheld, thereby producing the appreciable intermediate, the 
imine 12 (Figure 13b). After 2 hours, intermediates 13, 14, and 12 were produced; so, the reagent 
withheld from each intermediate (TOF for intermediates 13 and 14 and ethyl nitroacetate for 
intermediate 12, respectively) was added to each reaction mix, resulting in 10a. After several hours 
of recrystallization, it was readily apparent that the 10a reaction mix prepared from 12 formed 
more crystals. Even though the yields of the two reactions were comparable (due to an error during 
the workup process), the reagent order resulting in the appreciable imine intermediate was 
employed for all subsequent reactions.  
Synthesis of Enamine Intermediate 
with Aniline Derivatives 
The nucleophilic attack of the 
aniline derivative on TOF to form the 
imine intermediate is primarily 
dependent on the nucleophilicity of 
the aniline reagent. Upon successful 
synthesis of the enamine 10a, 
consisting of unsubstituted aniline, 
other aniline derivatives were tested 
as reagents to test their effect on the 
nucleophilic character and 
subsequent synthetic yield. The 
derivatives tested are displayed in 
Entry R Group R Group Structure Yield (%)
10a Ph 79
10b 3-MeOPh 84
10c 3-pyridine 93
10d 4-MeOPh 76
10e 4-NO2 85
10f 4-cyclohexyl 64
10g 2-NO₂ 18
10h 4-NHPh 56
10i 3-isoxazole 43
10
Table 1: Comparison of the yields obtained in the
synthesis of intermediate 10 with various derivatives of
aniline.
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Table 1. Enamine intermediates 10b and 10d, for example, include electron-donating groups 
(EDGs) (methyl ethers) at the meta and para positions on the aniline reagent. The inclusion of 
these EDGs did not significant affect the nucleophilicity of the derivative. This result is not 
surprising, considering the known positive correlation between negative charge and nucleophilic 
character. Thus, as the EDGs contribute electron density to the extended π-electron cloud, the 
nucleophilicity of the aniline derivative is increased. This nucleophilicity is also affected by the 
position of the substituent relative to the amine moiety. The EDGs present at the meta and para 
positions (10b, 10c, 10d, 10e) resulted in higher synthetic yields than the electron-donating 
substituent placed at the ortho position (10g). This trend can be explained by considering the sterics 
of the nucleophilic attack of the imine upon the TOF; substituents placed at the meta and para 
positions contribute to the electron density and thus nucleophilicity of the aniline derivative 
without interfering with the physical space within which the attack occurs. The EDG placed at the 
ortho position, however, sterically interferes with the nucleophilic attack and thus results in a lower 
synthetic yield. 
Other trends are readily observable within the set of aniline derivatives tested as reagents 
for the synthesis of the enamine intermediate. The importance of aromaticity—or rather, the even 
distribution of electrons along a cyclic, conjugated π-cloud—was also tested. Perturbations to the 
aromatic system, including aliphatic and heterocyclic derivatives, were included. The aliphatic 
aniline derivative, 10f, resulted in a slightly lower yield, suggesting that aromatic character 
contributes to the nucleophilicity of the derivative. The heterocyclic systems tested, the pyridine 
and isoxazole rings, had starkly different results in terms of synthetic yield. While the pyridine 
derivative 10c increased the synthetic yield, the isoxazole derivative decreased the yield 
drastically. This difference in synthetic yield can be attributed to a variety of factors, including the 
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nature of the heterocycles themselves: the pyridine is structurally similar to the benzene ring 
present on the original aniline derivative, and thus is not a significant departure from this aromatic 
and electronic system. The isoxazole, on the other hand, contains both an oxygen and nitrogen 
atom on a five-membered ring, thereby condensing the electronic system and contributing an extra 
lone pair of electrons via the oxygen atom. The decreased distance between the oxygen and 
nitrogen atoms within the heterocycle could also have contributed to an interference effect and 
thus resulted in decreased nucleophilicity. In any case, aromaticity of the aniline derivative was 
found to be an important factor in the nucleophilic attack on the TOF. 
Steric hindrance was also tested for its effect on nucleophilicity, with the hindered 
diphenylamine 10h affording a lower synthetic yield than its unhindered counterparts. The 
diphenylamine in particular offers a particularly interesting possible derivative for the desired 
product 11; the inclusion of a third ring system produces new possibilities for binding pockets 
within potential biochemical targets. The planarity of the phenyl rings and free rotation about the 
secondary amine offers new avenues for exploration. Certain proteins include hydrophobic pockets 
that interact favorably with phenyl rings. This occurs via cation-π-cloud interactions, with positive 
residues such as lysine and arginine capable of forming ion-dipole interactions with the phenyl 
ring or heterocyclic derivatives.38 
Recrystallization 
The recrystallization process for the synthesis of the intermediate was also explored to optimize 
yield. Since the enamine intermediate forms a basis for subsequent experiments concerning 
imidazole formation, the enamine was synthesized on the gram scale to provide plentiful starting 
material. Since the yield of the enamine hinges upon successful recrystallization and retrieval of 
the product from solution, this portion of the synthesis was optimized. Recrystallization was 
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optimized by scratching the glass of the round bottom flask, providing a point for the seed crystal 
to grow. Crystal growth occurs in two primary phases: nucleation, where a seed crystal is formed, 
and growth, where particles adhere to the seed crystal, forming a larger crystal in a process known 
as Ostwald ripening.41 Scratching the bottom of the round bottom flask provides infinitesimally 
small pieces of glass (seed crystals) that the particles in solution can adhere to, at which point the 
growth phases begins and Ostwald ripening occurs. Additionally, rather than using a 0°C ice bath, 
the round bottoms were placed in a -20°C freezer. These modifications to the protocol—including 
altering the order of reagent addition and modifying the round-bottom flask to obtain more product 
crystals—optimized the synthetic process for the enamine intermediate beyond experimentation 
with aniline derivatives. 
Overview of Imidazole Synthesis 
After formation of the enamine intermediate 10a, the next step is the reduction and 
cyclization to the substituted imidazole 11. Beyond successive modification of the enamine 
intermediate, the main synthetic challenged posed by this research proved to be the formation of 
the imidazole target. The first goal was to repeat the initial procedure outlined by Eidam et al. and 
synthesize the substituted imidazole where the R-group at position 2 was a hydrogen (rather than 
the alkyne found on the target 1,2,4-imidazole). Throughout this research, many hypotheses were 
formulated and tested in an effort to isolate and eliminate the difficulties encountered during the 
synthesis. Although the synthetic yield for the imidazole remained around 26% after multiple 
trials, the empirical knowledge gained throughout the experimentation has improved the process 
tremendously. This knowledge, ranging from reagent conditions to workup steps, continues to 
provide insights into the imidazole synthesis. The reagent conditions were iteratively optimized 
through several series of experiments and encompassed categories such as temperature, reaction 
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duration, reagent quality and type, and 
atmospheric conditions. These experiments 
were conducted in an effort to optimize the 
separate processes of reduction and cyclization 
of the enamine intermediate.  
Mechanism of Imidazole Formation 
The protocol for the synthesis of the 
imine called for the one-pot reduction of the 
nitro group on the enamine intermediate 
followed by the cyclization of the enamine. The 
mechanism of the cyclization (Figure 14) is an 
acid-catalyzed nitrogen-carbon bond forming 
reaction followed by formation of the aromatic 
imidazole. After reduction of the nitro group of 
the enamine to a primary amine, this 
nucleophilic moiety attacks the electrophilic 
TOF. The TOF functions as a protected carbon 
source and provides the fifth atom of the 
imidazole ring. After the initial nucleophilic 
attack, the secondary amine attacks the 
protonated acetal to form the imidazole ring. Further proton transfer (wherein a final equivalent of 
ethanol is forced to leave to form the aromatic ring) yields the desired imidazole 11. This reduction 
Figure 14: Mechanism for the cyclization of the
enamine intermediate into the desired imidazole
11, which proceeds via the acid-catalyzed attack
of the reduced enamine intermediate on the TOF,
which functions as a protected carbon source (the
fifth atom of the imidazole ring). Subsequent
elimination of the EtOH affords the aromatic
imidazole ring.
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and cyclization process thus consists of a complicated mechanism with multiple opportunities for 
optimization and modification.42  
Monitoring Reaction Progress 
One of the first optimizations that was made to the imidazole synthesis was the 
development of a method for viewing the progress of the reaction via thin-layer chromatography 
(TLC). Due to the nature of the reaction, which includes iron particulates and acetic acid, both of 
which severely hinder the image produced under TLC, so it was necessary to develop a workup 
(the process of isolating a pure product from the reaction mixture) capable of allowing the progress 
of the reaction to be observed. The methodology developed involved a “miniature workup” 
composed of removing the iron by filtering a 0.5 mL sample of the reaction mixture through a 
pipette packed with celite, followed by drying the sample in vacuo (removing the EtOH and some 
AcOH) and neutralizing any remaining AcOH with sodium bicarbonate. The organic product was 
taken up in ethyl acetate and TLC samples for spotting were drawn from this organic layer. This 
methodology provided information about the progress of the reaction and disappearance of the 
starting material without sophisticated tools such as an HPLC or LC-MS.  
Energetic Considerations 
Beyond development of techniques for monitoring the reaction progress, the reaction itself 
was optimized to improve yield. One of first variables that was experimented upon was the 
temperature of the reaction. The energetic barrier for an intramolecular cyclization reaction, for 
example, is higher than for a comparable intermolecular collision reaction. In the former case, the 
substrate molecule must undergo a conformational change from its low-energy state to a high-
energy, reactive transition state. This is a non-spontaneous reaction, and as such, must be 
accompanied by abundant, available free energy in order to proceed.38 An intramolecular 
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cyclization reaction therefore must 
overcome a large, positive Gibbs free 
energy activation energy barrier. This 
energy barrier is displayed in Figure 
15, with the activation energy (EA) 
representing the Gibbs free energy 
(ΔG) available in the system. The 
imidazole product (B) has a lower 
energy than the enamine starting 
material (A) because of the 
energetically stable nature of the heterocycle; the distributed electronic character of the pi-cloud 
provides greater thermodynamic stability compared to the relatively reactive enamine intermediate 
containing two amines. In an attempt to optimize the yield of the 1,2,4-imidazole, the temperature 
at which the enamine was refluxed with the Fe, TOF, EtOH, and AcOH was modified. The patent 
by Eidam et al. suggested refluxing the reaction at 90°C which effectively vaporized the ethanol 
(bp = 78°C) and partially vaporized the acetic acid (bp = 118°C). Several different approaches 
were taken in refluxing the reaction, and considering the relatively high energetic barrier posed by 
the intramolecular cyclization reaction, temperatures as high as 165°C were explored. By contrast, 
literature was found detailing the iron-mediated reduction of nitro compounds to amines and 
subsequent trimolecular condensation in a one-pot synthesis. While the mechanism did differ 
slightly, with the target molecule being formed via in situ intermolecular interactions, the 
similarities between the synthesis of the 1,2,4-imidazole and the 3,5-diarylpyridines were 
recognized. The paper reported achieving optimal yields with 30 minute reactions held at room 
Figure 15: Schematic reaction coordinate diagram of the reduction
and cyclization of the enamine 10a (A) intermediate into the imidazole
11 (B), detailing the activation energy (EA) required to cyclize the
intermediate. The stable transition state (I) is the reduced nitro
enamine 15.
10a 11a
15
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temperature.43 This approach was attempted, but unfortunately, no imidazole product was 
observed (and appropriately no starting material disappearance). The discrepancy between the 
syntheses of the 1,2,4-imidazole and the 3,5-diarylpyridine can possibly be attributed to the 
intramolecular nature of the cyclization of the imidazole. 
Mechanism of Nitro Reduction 
While the molecule does undergo several transition 
states, including the formation of complexes with the TOF 
(the diacetal protecting group forming a tertiary amine), the 
intermediate represented by the valley in the reaction 
coordinate diagram (I) is the enamine intermediate with the 
primary amine (formerly the nitro group) that was reduced 
by the presence of iron in acidic media. Understanding the 
mechanism of the reduction of the nitro group to the amine 
involves understanding the catalytic hydrogenation 
mechanism of iron (Fe) (Figure 16).44 The iron catalyst is oxidized from its Fe0 state to Fe2+ and 
is bound by the nitro moiety of the enamine intermediate. The complex formed is formally known 
as an organic nitroso (or C-nitrosoalkene complex) rather than an nitrosyl complex (which refers 
to a free NO group chelating a metal center). The bond angle of the organic nitroso complex differs 
from the 180° angle normally found in nitrosyl ligand complexes. This can be attributed to the 
electrons donated by the nitrogen atom; if the nitrogen atom functions as 1-electron donor (rather 
than a 3-electron donor), the bond angle is closer to 120-140°, with the N atom being sp2 
hybridized. In terms of reduction to a primary amine, the process occurs in two steps: (1) the 
organic nitroso complex is reduced initially to a hydroxylamine group, where two protons are 
Figure 16: Mechanism for the reduction
of the nitro moiety found on the enamine
intermediate 10a into a primary amine
capable of cyclization into the imidazole
11. The reduction proceeds through two
steps, with an Fe catalyst (M) acting as
the reducing agent.
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added to the nitroso, and (2) the hydroxylamine is further reduced with two additional protons, 
forming water and the primary amine (Figure 16).44 One of the primary problems encountered in 
the research was the difficulty in the removal of the catalytic iron from the reaction mixture post-
reduction. This difficulty can be attributed to the nature of the enamine intermediate when 
considered as a chelating ligand. Upon formation of the organic metal nitroso complex, free 
rotation about the double bond of the enamine could bring the secondary amine in proximity to the 
chelated iron. Since amines are classified as generally hard ligands and Fe ions are generally hard 
metal centers, the complexes formed between these species are more stable according to Hard-Soft 
Acid-Base Theory.45 If free rotation brought the nitroso-bound iron into contact with another 
nitrogen, a bidentate, stable complex could result and hamper reduction, cyclization, and the 
subsequent removal of the iron.45 Beyond chelation, employing iron powder in the reaction flask 
posed a practical problem; no matter what filtration system (usually celite or silica) was used or 
the number of times filtrated, iron powder was found after drying the product in vacuo. To 
ameliorate the issue of iron removal, various iron sources were tested for the catalytic efficiency, 
including iron powder, granular iron, iron strips, and iron chips. An attempt was thus made to 
strike a balance between surface area available for oxidation of elemental Fe to ionic iron and the 
practical problem of removing the iron particulates via filtration. Based on product formation 
monitored via thin-layer chromatography, it was found that granular iron offered catalytic activity 
without compromising ease of filtration.  
Reaction Conditions Tested  
Based on the mechanistic insights discussed earlier and other literature protocols, a large-
scale optimization of the reduction and cyclization process was undertaken. Several other metal 
sources were tested for their ability to function as reducing agents and were selected based on 
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immediate availability: iron strips, iron chunks (larger than granular iron), powdered zinc, and 
granular zinc. Zinc was chosen not only for its immediate availability, but due to the similarity of 
its cation Zn2+ to Fe2+, in terms of both being relatively hard acids (HSAB Theory).46 Both 
powdered and granular Zinc, however, were determined to be insufficient for the reduction of the 
nitro group. Zinc has been shown to reduce nitroso compounds to N-substituted hydroxylamine, 
but not to the desired primary amine. Finally, to maintain catalytic activity of the granular iron, 
the reaction flask was sparged with N2 and kept under N2 for the duration of the reaction. An 
immediate color change was observed in the reaction flask: whereas previous reductions resulted 
in a dark brown solution (characteristic of oxidized iron), performing the reduction in a nitrogen 
atmosphere prevented oxidation of the iron and resulted in a light yellow solution. This improved 
both the conditions of the reduction and the ease of the workup.  
 Other optimizations were attempted, including an extensive experimentation of the 
reagents employed in the synthesis. Of the four reagents present in the synthesis (excluding the 
enamine intermediate), two reagents were considered for modification: the proton source and the 
reducing agent. While Eidam et al. reported using AcOH for the synthesis of their imidazole, the 
efficacy of the acetic acid in providing protons for the reduction of the nitro group and the 
subsequent proton transfer reactions was tested. AcOH has a dissociation constant (pKa) of 4.76 
and is therefore classified as a weak acid.38 Since AcOH is a weak electrolyte, the amount of ionic 
dissociation (and thus free protons) is lower than for a solution containing a stronger acid with a 
larger dissociation constant. This, in turn, could affect how the reaction proceeds, with the 
availability of protons for the iron-mediated reduction, the nucleophilic amines, or diacetal 
protecting groups that require protonation to function as leaving groups directly affecting the 
mechanism. As a result of this consideration, another proton source was tested, hydrochloric acid. 
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This strong acid dissociated completely in solution, leaving behind a spectator anion and 
contributing protons to the reaction. Less HCl was required for the reaction given its high 
Metal Proton Source
Reagent 
Equivalencies
Δ 
(°C)
Reaction 
Flask Purged 
w/ N2
Workup TLC Producta
% 
Yield
Fe 
(powder) AcOH
Fe (10)
TOF (10) 90 N celite Y 26
Fe 
(powder) AcOH
Fe (10)
TOF (10) 95 N silica Y 25
Fe 
(powder) EtOH/HCl
Fe (10)
TOF (10) 95 N silica N N/A
Fe 
(powder) AcOH
Fe (10)
TOF (10) 140 N silica N N/A
Fe 
(powder) AcOH
Fe (10)
TOF (10) 160 N silica Y N/A
Fe 
(powder) AcOH
Fe (10)
TOF (10) 140 N N/A Y N/A
Fe 
(granular) AcOH
Fe (10)
TOF (10) 140 N N/A Y N/A
Fe (chips) AcOH Fe (10)TOF (10) 140 N N/A N N/A
Fe (strips) AcOH Fe (10)TOF (10) 140 N N/A N N/A
Fe 
(powder) AcOH
Fe (3)
TOF (3) rt N N/A N N/A
Fe 
(granular) AcOH
Fe (3)
TOF (3) rt N N/A N N/A
Zn 
(powder) AcOH
Zn (10)
TOF (10) 100 Y N/A N N/A
Zn 
(granular) AcOH
Zn (10)
TOF (10) 100 Y N/A N N/A
Fe 
(granular) AcOH
Fe (3)
TOF (3)
80-
100 Y N/A Y N/A
Fe 
(granular) AcOH
Fe (10)
TOF (13) 90 Y N/A Y N/A
Fe 
(granular) AcOH
Fe (10)
TOF (13) 85 Y silica Y 26
Table 2: Iteratively tested variables for the synthesis of imidazole 1. Variables tested include
metal source, proton source, reagent equivalencies, reaction temperature, the presence of an
inert nitrogenous atmosphere, and workup conditions.
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dissociation constant, and it was introduced a solution in ethanol. Unfortunately, no product 
formation was observed when this acid was employed.  
Characterization of Product 11 
Thus, the final optimized reaction for the synthesis of the 1,2,4-imidazole employed 
granular iron and acetic acid, refluxed at 85°C and kept under N2 gas. The various variables tested 
throughout the course of the research are summarized in Table 2. Yet, even with the optimizations 
made to the reaction, a yield of only 26% was obtained. The reaction was monitored hourly for 
starting material disappearance and product formation, and the TLC plate confirms nearly 100% 
starting material conversion. The low yield obtained after purification lends credence to the 
hypothesis that the work-up of the reaction results in product loss. Several explanations can be 
presented for the location of the product post-workup: (1) if the product is not formed entirely—
possibly an incomplete cyclization could result in the diacetal protecting group remaining on the 
enamine intermediate—then the compound becomes decidedly more polar and could be lost to the 
aqueous layer of the workup, or (2) since silica gel (employed in column chromatography as the 
stationary phase) is slightly acidic, hydrogen bonding may occur between the various moieties of 
the 1,2,4-
imidazole 
product. 
Additionally, 
incomplete 
formation of 
product 11 is 
possible, with 
1.52.02.53.03.54.04.55.05.56.06.57.07.58.0
f1	(ppm)
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Figure 17: 1H NMR of synthesized imidazole 11, which was obtained in 26% yield following
extensive optimization of reaction variables.
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the mechanism of the imidazole reduction and cyclization affording several remotely stable 
intermediates. Heterocycles present a unique synthetic challenge due to the nature of their 
electronic environment; nearly the entire 1,2,4-imidazole product is conjugated, potentially 
allowing electron movement across the molecule and creating a variety of opportunities for 
subsequent proton transfer and hydrogen bonding. Further work must be done to determine the 
exact cause of product loss in the steps of the workup. The 1H NMR of the 1,2,4-imidazole product 
is displayed in Figure 17. The HE proton is assigned to the peak farthest downfield due to its 
proximity to the electronegative ester moiety. 
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V. Future Directions 
Metal-Free Reduction 
Future directions of this research follow two 
main motifs: (1) possible optimizations for the 
synthesis of the 1,	 2,4-imidazole, and (2) upon 
optimization of the synthesis, development of a 
fragment library by employing the synthetically 
tractable alkyne moiety and substitution of the phenyl 
ring at the 1-position. One of the most exciting 
possible optimizations available for the reduction of 
the nitro moiety is the recently discovered metal-free 
reduction of nitro compounds via trichlorosilane 
(HSiCl3). This process, which provides an alternative to the iron-mediated reduction, could be 
advantageous both to product formation and to the workup of the reaction itself. Orlandi et al. 
report a chemoselective and widely applicable trichlorosilane reducing agent (Figure 18).47,48 This 
reaction must proceed in an inert environment, as upon exposure of trichlorosilane to water, a 
silicon polymer and hydrochloric acid are rapidly produced.  
Addition of the 2-position Substituent 
Additionally, another optimization to the synthesis is available in the form of the TOF 
reagent; TOF functions as both as a diacetal protecting group and a carbon source for position 2 
of the 1,2,4-imidazole. If the proton of TOF (highlighted in Figure 19) were modified to an alkyne 
moiety, for example, or to a primary amine, the synthesis of the fully substituted 1,2, 4-imidazole 
Figure 18: Possible future direction for the
reduction of enamine intermediate 10a into
primary amine 15 for cyclization into imidazole
11, the employment of the metal-free reducing
agent trichlorosilane(HSiCl3).
HSiCl3
R3N10a 15
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would 
skip 
several 
steps by 
placing 
these new 
moieties 
at the 2 
position. 
While this synthesis was explored (propargyl aldehyde was ordered and employed several times 
in the reduction and cyclization reactions), focus was placed instead on the initial imidazole 
formation (with TOF) rather than wasting a valuable reagent in the optimization stage.  
Development of Imidazole 1 into Fragment Library 
 Once the imidazole synthesis has been optimized and the 1,2,4-imidazole has been 
produced in appreciable quantities, exciting opportunities exist to take advantage of the readily-
substituted alkyne synthetic handle and phenyl ring at positions 1 and 2, respectively. These 
substitutions allow for rapid diversification of the 1,2,4-imidazole into a variety of different 
molecules that could constitute the basis of a fragment library, the overarching goal of this 
research. This is where the importance of the 1,2,4-imidazole’s synthesis becomes apparent; at the 
diversification stage, the 1,2,4-imidazole offers an unprecedented ability for optimization and 
modification when compared to other imidazole syntheses. Indeed, plentiful potential reactions 
exist for the synthetic handle, including the aforementioned Sonogashira coupling, catalytic 
hydrogenations, acetylide nucleophilic additions, or Huisgen cycloadditions. A combination of 
A
B
1 (R=H)
1 (R=H)
Figure 19: Employing propargyl aldehdye (highlighted in B) is a more efficient method of
placing alkyne at position 2 obtaining the desired imidazole 1 (where R = H) and
subsequently exploring various moieties via the synthetic handle, rather than (A) where a
radical bromination to 16, substitution of TMS to 17, and removal of TMS is required to
place alkyne at position 2.
8
6 16 17
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these alkyne syntheses and the various phenyl derivatives produced during the expansion of the 
enamine intermediate library would results in a vast array of molecules, each with unique moieties 
and electronic environments. This diversity relates back to tenants of FBDD that were introduced 
earlier, including a balance being struck between potentially favorable biochemical interactions 
and the relatively small size of the molecule itself. At a molecular weight around 300 amu, the 
1,2,4-imidazole and its derivatives are small molecules with complex moieties and heterocyclic 
components that can form numerous favorable interactions with biochemical pockets.  
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